Private equity’s footprint in physician practices has expanded sharply over the past decade, but the debate over its consequences has often generated more heat than clarity.
A pair of recent analyses — a Commonwealth Fund feature published in April and a Bain & Company global healthcare private equity report — offer a more nuanced picture of what PE ownership actually changes, and what it doesn’t.
Here are five things the research shows.
1. The buy-and-build era is over. The maturation era has begun.
The initial frenzy of platform acquisition has cooled, according to the Bain report. What’s replaced it is a more selective, operationally focused model in which investors are targeting practices with demonstrated management depth, strong commercial payer mix and scalable ancillary revenue.
2. Physicians in ASC-adjacent specialties are increasingly the target.
The Bain report identified GI/endoscopy and orthopedics/spine as segments where “sustained high demand” and ambulatory migration are preserving premium valuations. The Commonwealth Fund analysis reached a similar conclusion: specialties where high-value outpatient procedures can be performed quickly, such as endoscopies, joint replacements and biopsies, remain the most attractive targets for consolidation.
3. PE capital enables the outpatient shift but also accelerates dependence on it.
The Commonwealth Fund piece highlighted urology as a case study: practices that lack the upfront capital to offer radiation therapy, immunotherapy or oral oncolytics in outpatient settings are increasingly disadvantaged against larger, PE-backed competitors that can absorb those infrastructure costs.
4. The overhead problem is real and recurring.
The Commonwealth Fund piece included an on-the-record account from an orthopedic surgeon in Florida who said PE ownership added layers of management — executives in business development and marketing — that function as “cost centers” rather than revenue generators. He had structured deals himself before medical school and said the financial engineering was designed to benefit the acquirer, not the acquired.
5. Regulatory scrutiny is now a material deal variable.
Both analyses noted that the compliance environment has shifted. The Bain report found that investors are now demanding more rigorous clinical outcomes data and governance paper trails before closing deals, in part because antitrust enforcement has become less predictable.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.